Chargement en cours...
Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib
Palbociclib is a CDK4/6 inhibitor approved for metastatic estrogen receptor‐positive breast cancer. In addition to G1 cell cycle arrest, palbociclib treatment results in cell senescence, a phenotype that is not readily explained by CDK4/6 inhibition. In order to identify a molecular mechanism respon...
Enregistré dans:
| Publié dans: | EMBO J |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5978322/ https://ncbi.nlm.nih.gov/pubmed/29669860 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embj.201798359 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|